BiopSense develops solutions and services for liquid biopsy monitoring of cancer. With the number of treatment options constantly increasing, more frequent monitoring helps the oncologists to respond more quickly, in case the treatment is not satisfactory, or a drug resistance is induced. As a result, the patient will receive the correct treatment faster. Cancer medications are often expensive and predicting the effect could be hard, but they can also have the potential to completely cure the cancer. That is why it is important to get the medication right as soon as possible. Therefore, screening for cancer with BiopSense is an effective way to improve the quality of cancer treatments and to reduce the cost.
BiopSense is medtech company founded in Jyväskylä, Finland. BiopSense was born from a research project at the University of Jyväskylä. We have a diverse and committed core team with extensive expertise from nanosciense to oncology. We co-operate with Business Finland and Startup Factory of Jyväskylä. Please feel free to contact us if you are interested in hearing more from us.